BioNumerik Pharmaceuticals, Inc.

ACTIVE

8023 Vantage Dr, 德克萨斯州比尔县, Texas, United Statesbionumerik.comPrivate51–100 employeesEstablished: 1992-01-01

Clinical Trials

6 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1992

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

25.0%

Phase 1

16.7%

Phase 2

16.7%

Trial Status Distribution

Active, not recruiting

50.0%

Completed

50.0%

Clinical Trials

Trials sponsored by this organization (12)

Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

Phase 3

Completed

interventional

Apr 2010540 participants

Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced primary adenocarcinoma of the lung treated with docetaxel or paclitaxel plus cisplati

Active, not recruiting

Dec 2009575 participants

Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with docetaxel or paclitaxel plus cisplati

Active, not recruiting

Jul 2009575 participants

A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER

Active, not recruiting

Dec 2007500 participants

A Phase 3 study of safety and efficacy of Karenitecin versus topotecan administered for 5 consecutive days every 3 weeks in patients with advanced epithelial ovarian cancer

Active, not recruiting

Aug 2007500 participants

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

Phase 3

Completed

interventional

Aug 2007509 participants

A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER

Active, not recruiting

Jul 2007500 participants

A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER

Phase 1

Active, not recruiting

Jul 2007500 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations